| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1383 | 2017 |
| Tumour heterogeneity in the clinic PL Bedard, AR Hansen, MJ Ratain, LL Siu Nature 501 (7467), 355-364, 2013 | 1353 | 2013 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1154 | 2020 |
| Sensitive tumour detection and classification using plasma cell-free DNA methylomes SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ... Nature 563 (7732), 579-583, 2018 | 754 | 2018 |
| A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, ... Annals of Oncology 29 (9), 1895-1902, 2018 | 587 | 2018 |
| Novel patterns of response under immunotherapy E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ... Annals of Oncology 30 (3), 385-396, 2019 | 464 | 2019 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 436 | 2020 |
| Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling HA Azim Jr, S Michiels, PL Bedard, SK Singhal, C Criscitiello, M Ignatiadis, ... Clinical cancer research 18 (5), 1341-1351, 2012 | 436 | 2012 |
| Small molecules, big impact: 20 years of targeted therapy in oncology PL Bedard, DM Hyman, MS Davids, LL Siu The Lancet 395 (10229), 1078-1088, 2020 | 430 | 2020 |
| The genetic basis for cancer treatment decisions JE Dancey, PL Bedard, N Onetto, TJ Hudson Cell 148 (3), 409-420, 2012 | 422 | 2012 |
| Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ... Journal of the National Cancer Institute 106 (1), djt319, 2014 | 406 | 2014 |
| Luminal-B breast cancer and novel therapeutic targets B Tran, PL Bedard Breast Cancer Research 13 (6), 221, 2011 | 350 | 2011 |
| Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance C Kollmannsberger, T Tandstad, PL Bedard, G Cohn-Cedermark, ... Journal of Clinical Oncology 33 (1), 51-57, 2015 | 347 | 2015 |
| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 345 | 2020 |
| Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ... Clinical Cancer Research 24 (12), 2804-2811, 2018 | 327 | 2018 |
| A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with … PL Bedard, J Tabernero, F Janku, ZA Wainberg, L Paz-Ares, ... Clinical Cancer Research 21 (4), 730-738, 2015 | 320 | 2015 |
| International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy F Cardoso, PL Bedard, EP Winer, O Pagani, E Senkus-Konefka, ... Journal of the National Cancer Institute 101 (17), 1174-1181, 2009 | 310 | 2009 |
| AKT Inhibition in Solid Tumors With AKT1 Mutations DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ... Journal of Clinical Oncology 35 (20), 2251-2259, 2017 | 299 | 2017 |
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ... Genome medicine 8, 1-12, 2016 | 253 | 2016 |
| Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, ... Clinical Cancer Research 27 (13), 3620-3629, 2021 | 231 | 2021 |
Lillian SiuPrincess Margaret Cancer CentreVerified email at uhn.ca
